Research and Markets (http://www.researchandmarkets.com/research/gvfxph/global_tumor) has announced the addition of the "Global Tumor Ablation Market 2015-2019" report to their offering.
Tumor ablation is a minimally invasive, image-guided treatment procedure that is used to destroy cancer cells in the chest, lung, and liver. Recent advances in semiconductor technology and modifications to the design of medical laser systems such as MRI or ultrasound are responsible for this markets healthy growth rate of more than 15% during the forecast period.
Geographically, the EMEA region is expected to account for the highest market share during the forecast period. The growing prevalence of cancer in countries such as Denmark, Belgium, France, and Norway is responsible for this regions high market share of close to 37% by 2019.
Segmentation by ablation technology and analysis of the tumor ablation market:
- Radiofrequency
- Ultrasound
- Cryotherapy
-
Microwave
The report estimates the radiofrequency segment to account for approximately 13% of the total market share by 2019. Radiofrequency is very specific for treating target tissues without causing significant damage to surrounding healthy cells. The high efficacy rate of this procedure is expected to bolster its growth during the forecast period.
Companies Mentioned:
- AngioDynamics
- Boston Scientific
- Ethicon
- Medtronic
- Alpinion Medical System
- BSD Medical
- Conmed
- C2 Therapeutics
- CSA Medical
- C.R. Bard
- Chongqing Haifu Medical Technology
- Esaote
- EDAP TMS
- Galil Medical
- InSightec
- Misonix
- Mermaid Medical
- Monteris
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Cancer statistics
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by ablation technology
PART 09: Market segmentation by cancer types
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
PART 17: Key vendor analysis
For more information visit http://www.researchandmarkets.com/research/gvfxph/global_tumor
View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005731/en/